The US Food and Drug Administration is acknowledging the emerging interest in exploring therapeutic uses of psychedelic drugs, but does not sound overly “psyched” about the prospects.
The agency released draft guidance in late June offering its initial thinking on clinical development of psychedelic drugs. The guidance is a milestone in recognizing the burgeoning interest in exploring potential therapeutic applications of products like LSD, psilocybin and MDMA